Dianthus Therapeutics Inc Revenue Growth Rates (DNTH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Dianthus Therapeutics Inc   (NASDAQ: DNTH)
 

DNTH's Revenue Growth by Quarter and Year

Dianthus Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DNTH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.76
1st Quarter March 0.00
FY 0.76





DNTH Revenue second quarter 2026 Y/Y Growth Comment
Dianthus Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue surge of 300.53% year on year, to $ 0.76 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue growth. While Dianthus Therapeutics Inc ' s Revenue doubling of 300.53% ranks overall at the positon no. 167 in the second quarter 2026.


DNTH Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -78.95 % -30 % 62.39 %
3rd Quarter September - -81.57 % 135.87 % -21.37 %
2nd Quarter June 300.53 % -89.78 % - -
1st Quarter March - 33.33 % - -
FY   - -67.42 % 120.92 % -

Financial Statements
Dianthus Therapeutics Inc 's second quarter 2026 Revenue $ 0.76 millions DNTH's Income Statement
Dianthus Therapeutics Inc 's second quarter 2025 Revenue $ 0.19 millions Quarterly DNTH's Income Statement


DNTH Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -30 % -38.71 % 106.52 %
3rd Quarter September - 110.53 % 16.67 % -
2nd Quarter June - -83.62 % 113.79 % -
1st Quarter March - -12.78 % -54.21 % -
FY (Year on Year)   - -67.42 % 120.92 % -


Back to DNTH Growth rate Comparisons >> Back to DNTH Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #53
Overall #167

Revenue Y/Y Growth Statistics
High Average Low
294.3 % 10.27 % -100 %
(Jun 30 2025)   (Dec 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #53
Overall #167
Revenue Y/Y Growth Statistics
High Average Low
294.3 % 10.27 % -100 %
(Jun 30 2025)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Dianthus Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DNTH's II. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DNTH's II. Quarter Q/Q Revenue Comment


Dianthus Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 2.04 $ 3.08 $ 4.85
Y / Y Revenue Growth (TTM) - - -67.35 % -54.81 % -12.74 %
Year on Year Revenue Growth Overall Ranking # 3813 # 3525 # 2183 # 2847 # 1759
Seqeuential Revenue Change (TTM) - - -33.85 % -36.59 % -25.6 %
Seq. Revenue Growth (TTM) Overall Ranking # 4076 # 2157 # 3221 # 545 # 243


Cumulative Revenue growth Comment
Dianthus Therapeutics Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2026, compare to Revenue of $ 5 millions a year ago.

In the Healthcare sector 483 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3525 to 3813.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 173
Healthcare Sector # 484
Overall # 3813

Revenue TTM Y/Y Growth Statistics
High Average Low
-12.74 %
 -44.97 %
-67.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 173
Sector # 512
S&P 500 # 4076
Cumulative Revenue growth Comment
Dianthus Therapeutics Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2026, compare to Revenue of $ 5 millions a year ago.

In the Healthcare sector 483 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3525 to 3813.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 173
Healthcare Sector # 484
Overall # 3813

Revenue TTM Y/Y Growth Statistics
High Average Low
-12.74 %
-44.97 %
-67.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 173
Sector # 512
S&P 500 # 4076




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DNTH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions
Kymera Therapeutics Inc 466.40%$ 466.399 millions
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions
Miragen Therapeutics Inc 278.67%$ 278.667 millions
Alpha Cognition Inc.267.56%$ 267.556 millions
Agios Pharmaceuticals Inc 259.25%$ 259.253 millions
Omniab Inc 244.24%$ 244.239 millions
Medicinova Inc 240.60%$ 240.596 millions
Clene Inc 233.33%$ 233.333 millions
Editas Medicine Inc 232.31%$ 232.309 millions
Urogen Pharma Ltd 206.17%$ 206.174 millions
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions


About Dianthus Therapeutics Inc Revenue Growth Rates (DNTH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Dianthus Therapeutics Inc (CIK 1690585).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001690585-26-000034
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Dianthus Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.